For decades, the fight against baldness has been framed as a choice between harsh pharmaceuticals and cosmetic cover ups. Now a centuries old Chinese root, long brewed in village kitchens and traditional clinics, is being dissected in modern labs as a potential third way. Polygonum multiflorum, better known as He Shou Wu, is emerging not as a mystical cure but as a multi target drug candidate that could reshape how I think about common hair loss.
The core claim from researchers is stark: this is not folklore dressed up as wellness marketing, it is a pharmacological toolkit hiding in a gnarled piece of plant. Early data suggest the herb may influence inflammation, hormone signaling, and follicle regeneration at once, a very different strategy from today’s single pathway drugs. The science is still early and far from definitive, but the direction of travel is clear enough to take seriously.
The ancient root under the microscope
Polygonum multiflorum has been part of Chinese medical practice for centuries, prescribed as He Shou Wu for hair graying, fatigue, and longevity, yet only recently has it been systematically mapped against modern definitions of androgenetic alopecia. A detailed review described how the herb’s long history of use is now being parsed into specific bioactive compounds and pathways, treating the root less as a talisman and more as a complex chemical library. That work, led by first author Han bixian, is framed explicitly as an effort to bridge traditional pattern based diagnosis with molecular targets that can be measured and replicated.
In that analysis, Han and colleagues sifted through lab experiments, clinical reports, and classical herbal records to build a composite picture of how Polygonum multiflorum might act on hair follicles over time. The review, highlighted through Our analysis, argues that the root appears to influence several biological processes relevant to hair cycling rather than just blocking a single hormone. A companion summary of the same work notes that the authors see their project as “bridging ancient wisdom and modern science,” a phrase that captures both the ambition and the risk of overpromising on early stage data.
How Polygonum multiflorum differs from standard drugs
Most people confronting thinning hair today are offered a narrow menu: finasteride to inhibit one enzyme in the androgen pathway, or minoxidil to nudge follicles into a growth phase, often with side effects and limited durability. By contrast, the new review suggests that Polygonum multiflorum appears to work differently, with evidence that its compounds may dampen inflammatory signals around follicles, modulate local hormone activity, and support stem cell driven regeneration in the follicle niche. That multi pronged profile is why some researchers now describe it as a potential “system level” intervention rather than a simple blocker.
Reporting on the review emphasizes that this centuries old Chinese medicinal root is being positioned as a possible option for common pattern hair loss in both men and women, not just a cosmetic tonic for graying. One summary notes that Polygonum multiflorum appears to act on multiple biological targets, which could, in theory, translate into better outcomes for people whose hair loss is driven by overlapping hormonal, inflammatory, and microcirculatory factors. That is a big “if,” but it is precisely the kind of mechanistic breadth that current single target drugs lack.
What the evidence actually shows so far
Strip away the hype and the current evidence base for He Shou Wu looks like a layered pyramid: animal models and cell cultures at the base, small human observations in the middle, and a conspicuous absence of large randomized controlled trials at the top. The review in the Journal of Holistic Integrative Pharmacy, described in detail through Ancient Remedy Revisited, pulls together data showing that extracts of Polygonum multiflorum can stimulate follicle cells in vitro and improve hair density in animal models. It also cites historical case records where the herb was associated with darker, thicker hair, though those accounts lack the controls modern readers expect.
A separate summary of the same body of work notes that the review synthesizes evidence from lab studies, clinical reports, and centuries old herbal records into a single framework for androgenetic alopecia. That synthesis, described through Polygonum, is valuable because it surfaces both promising signals and glaring gaps, including the need for standardized dosing, clear safety monitoring, and head to head comparisons with existing drugs. Until those gaps are filled, any claim that He Shou Wu “reverses” baldness in the real world remains unverified based on available sources.
Botanicals, fatty acids, and a changing hair loss playbook
Polygonum multiflorum is not emerging in isolation, it is part of a broader pivot toward plant based and integrative approaches to hair loss that treat the scalp as an ecosystem rather than a single receptor to be blocked. A comprehensive review of botanical drug preparations for hair loss, which prioritized each randomized controlled trial alongside in vitro and animal work, highlights saw palmetto (Serenoa repens) as one of the key remedies with evidence for androgen modulation. That same review notes that ginseng enhances follicle proliferation via ginsenosides, suggesting that multiple botanicals can act on overlapping pathways relevant to hair cycling.
Parallel experiments with topical monounsaturated fatty acids add another layer to this evolving toolkit. In one set of studies, researchers found that putting these fatty acids directly on the skin could help hair grow, a finding summarized through new research that points to barrier function and local metabolism as underappreciated levers. When I put these strands together, Polygonum multiflorum looks less like a lone miracle and more like one node in a network of plant derived and lipid based interventions that could be combined, sequenced, or layered with existing drugs.
Promise, risk, and the missing human trials
For all the excitement, the most sobering line in the current coverage is that large scale, randomized human trials of Polygonum multiflorum for androgenetic alopecia simply do not exist yet. One report, summarizing the state of play, stresses that the renewed attention to this Ancient Chinese herb is not just lab based curiosity but still rests heavily on preclinical data and small, uncontrolled observations. That context, captured in Han, is crucial because it tempers the narrative of a “game changer” with the reality that we do not yet know how the herb performs against placebo, or how it interacts with finasteride and minoxidil in real patients.
Another analysis framed Polygonum multiflorum as a hair regrowth herb that may offer a new approach, noting that unlike standard treatments that target a single biological pathway, this root appears to influence several mechanisms at once. That framing, outlined through Unlike, is compelling but also risky if it encourages people to abandon proven therapies for an untested alternative. The more responsible path, in my view, is to treat He Shou Wu as a candidate for combination regimens that must be evaluated in rigorous trials, not as a standalone cure that can be assumed safe and effective by default.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
